GlobeNewswire

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting

Share

LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled “TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)” will be presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in San Francisco. The poster (Abstract # TPS471) will be available at www.erytech.com after presentation at the conference.

In September 2018, the TRYbeCA-1 trial was initiated. The Trial-in-Progress poster will provide an update on the study progress with investigators sites that have been initiated in multiple countries and actively recruiting patients. The trial is planned to enroll approximately 500 patients with second line metastatic pancreatic cancer in 120-130 clinical sites in 12 European countries and the United states. Currently the trial is approved for patients participation in eight selected European countries, and enrolling patients in 21 clinical sites.

Patients who meet the eligibility criteria are randomized 1-to-1 to receive eryaspase in combination with standard chemotherapy (gemcitabine/abraxane or irinotecan-based regimen) or chemotherapy alone until disease progression. The primary endpoint is overall survival. An interim analysis is foreseen when approximately two-thirds of events have occurred.

The launch of the Trybeca-1 Phase 3 trial follows the positive Phase 2b results in the same patient population, that were reported in September 20171. This open-label, multi-center, 2-to-1 randomized study in 141 patients demonstrated significant improvement in both overall survival and progression-free survival. Overall, eryaspase was well tolerated and did not appear to increase the toxicity of the chemotherapy. 

“Patients with advanced pancreatic cancer need new treatment options. As global co-Principal Investigator, I am delighted with the rapid set-up of the study. The Trial-in-Progress poster demonstrates that we are making excellent progress toward the initiation of over 100 centers for TRYbeCA-1 ,” commented Dr. Manuel Hidalgo-Medina, medical oncologist at Beth Israel Deaconess Medical Center in Boston and professor of medicine at Harvard Medical School.  

“The results from our landmark Phase 2b study are highly promising and underscore the importance of targeting tumor metabolism pathways in pancreatic cancer. We are hopeful to provide a novel treatment modality for this highly unmet medical need. We are very pleased that the Phase 3 study is making excellent progress and patient enrollment continues as planned. Our enrolled patients mark the initiation of the trial in Europe. We expect investigator sites in the United States will begin enrolling this quarter,” commented Iman El-Hariry, Chief Medical Officer.

About pancreatic cancer

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Every year, there are approximately 150,000 new cases of pancreatic cancer diagnosed in Europe and the United States. Advanced pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. It is currently the fourth leading cause of cancer death in Europe and the United States and is projected to rise to the second leading cause by 2030. Limited therapeutic options are currently available for this indication, thereby reinforcing the need to develop new therapeutic strategies and rational drug combinations with the aim of improving overall patient outcomes and quality of life.

About ERYTECH and eryaspase (GRASPA®): www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.

ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS

ERYTECH    
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
i nvestors@erytech.com
+33 1 44 71 98 52
erytech@newcap.eu

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH’s product pipeline, its clinical development and regulatory plans for eryaspase, the timing of ERYTECH’s clinical studies and trials and announcements of data from those studies and trials, and the contents and timing of decisions by the FDA and EMA regarding ERYTECH’s product candidates. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2017 Document de Référence filed with the AMF in April 2018 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 24, 2018 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

____________________
1 Hammel et al, Annals of Oncology (2017) 28 (suppl_5): v209-v268

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Invitation to Q2 conference call21.8.2019 14:31:00 CESTPress release

Oslo, Norway, 21 August 2019 Vistin Pharma ASA will release its second quarter 2019 results on Thursday 29 August, 2019. Vistin Pharma will host a conference call for all shareholders and interested parties on 29 August at 08:00 CEST. There will be a Q&A session following the management discussion. The second quarter conference call will be available via web and audio through the following access points: Telephone conference: Confirmation Code:........ 9184908 International Dial-In: ..... +44 (0) 2071 928000 Norway, Oslo................. 23960264 United States, New York. 16315107495 Webcast: https://edge.media-server.com/m6/p/cvjpg4fj ***** For further information, please contact: Gunnar Manum CFO +47 95 17 91 90 gunnar.manum@vistin.com

Oboya receives an order in Poland21.8.2019 14:29:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya") has through its wholly owned subsidiary VEFI Europa Sp. z o.o in Skierniewice, Poland received an order for cultivation gutter from an existing customer in Poland. The order value amounted to about PLN 1.1 million, corresponding to about SEK 2.7 million. The order concerns delivery of cultivation gutter to hydroponic cultivation systems and will be delivered continuously during September 2019. The order value amounts to PLN 1.1 million, corresponding to approximately SEK 2.7 million. The existing customer F.H. Nowalijka Piotr Wychowałek is one of the leading hydroponic growing companies in lettuce and fresh herbs in Poland. The cultivation gutter will be used for hydroponic cultivation in greenhouses and grown without soil. VEFI was founded in 1949 and has been operating for 70 years and is a leading supplier of products for hydroponic cultivation systems. Hydroponic cultivation system means cultivation in greenhouses, regardless of cli

Oboya får en order i Polen21.8.2019 14:29:00 CESTPressemelding

Oboya Horticulture Industries AB (publ) (”Oboya”) har genom sitt helägda dotterbolag VEFI Europa Sp. z o.o i Skierniewice, Polen fått en order på odlingsrännor från befintlig kund i Polen. Ordervärdet uppgår till ca 1,1 MPLN, motsvarande ca 2,7 MSEK. Ordern avser leverans av odlingsrännor till hydroponisk odlingssystem och kommer att levereras löpande under september 2019. Ordervärdet uppgår till 1,1 MPLN, motsvarande ca 2,7 MSEK. Den befintliga kunden F.H. Nowalijka Piotr Wychowałek är ett av de ledande hydroponic odlingsbolag inom sallad och färska örter i Polen. Odlingsrännorna kommer att användas för hydroponisk odling i växthus och odlas utan jord. VEFI grundades 1949 och har varit verksamt i 70 år och är en ledande leverantör av produkter för hydroponisk odlingssystem. Hydroponisk odlingssystem innebär odling i växthus, oberoende av klimat med möjlighet att odla året runt. Odling i hydroponisk odlingssystem sker ofta i ett slutet- och självförsörjande system. Erik Penser Bank AB

Conference call 28 August at 10.00 (CEST) about Interim Report Q2 201921.8.2019 13:07:00 CESTPress release

21/08/2019 COMPANY ANNOUNCEMENT 11/2019 Goodvalley will release its Interim Report Q2 2019 on 27 August 2019. On 28 August 2019 at 10.00 (CEST), Goodvalley will host a conference call at which CEO Hans Henrik Pedersen and Vice CEO Kristian Brokop will provide comments on financial and operational performance in Q2 2019, the outlook and answer questions. Registration is not required. The conference call will be conducted in English and can be followed live here: https://edge.media-server.com/mmc/p/vuzfpixi Participants should dial the numbers provided below and state conference code Denmark: +45 32 72 80 42 Norway: +47 239 60264 Sweden: +46 (0)850 692180 Poland +48 222 120 152 United Kingdom: +44 (0)844 571 8892 United States: +1 631 5107495 Further Information Group Communications, Anne Axelgaard + 45 76 52 20 00 investor@goodvalley.com Goodvalley at a glance Goodvalley is an international producer of high quality pork products operating in Poland, Ukraine and Russia based on Danish pr

Rovio Entertainment Corp.: Vodafone and Hatch launch the first premium cloud gaming service in Germany21.8.2019 13:00:00 CESTPress release

Rovio Entertainment Corporation Press Release August 21, 2019 Vodafone and Hatch launch the first premium cloud gaming service in Germany Hatch’s mobile games streaming service now available for Vodafone 5G customers across Germany Available on Android 5G devices, Hatch is optimized for gaming as part of Vodafone’s 5G roll-out Hatch offers Vodafone 5G customers complimentary access to Hatch Premium, which includes unlimited access to more than 100 premium games Vodafone and Hatch, Rovio Entertainment Corp. subsidiary, today announced the launch of the first 5G-optimised cloud gaming service in Germany. Introduced as part of Vodafone Germany’s 5G switch-on, avid and casual gamers alike will be able to stream games instantly from their Android 5G-enabled devices. The Hatch app is now available to download from the Google Play Store. Vodafone 5G customers will have 3-months of complimentary access to Hatch Premium, Hatch’s subscription level plan. After this period, the service will cost